Neonc Technologies Holdings, Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
NTHI · Price history
Price at last available close
$3.03
−$0.27 (-8.18%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Neonc Technologies Holdings, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
How they make money
NeOnc Technologies Holdings, Inc. is a clinical-stage biotechnology company that focuses on the development of novel molecular technologies for treating central nervous system diseases, including brain cancer. The company currently operates in a research and development phase, focusing on advancing its proprietary drug candidates through clinical trials rather than generating commercial revenue from product sales.
Products & services
The company's primary product candidates are NEO100, a purified form of perillyl alcohol, and NEO212, a dual-action molecule combining perillyl alcohol and temozolomide, both designed for the treatment of brain tumors.
Brands & revenue mix
Lead product candidate for brain tumor treatment.
Separate brand revenue is not available in this research.Source
Dual-action molecule product candidate.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Healthcare providers and medical institutionsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct and manage its clinical trials.Source
Business relationships & partnerships
- NuroMENA — A UAE-based subsidiary focused on advancing regional partnerships and strengthening Abu Dhabi–US collaboration in brain cancer treatment.Source
Competitors
- Pharmaceutical and biotechnology companies — The company competes with various entities developing therapies for central nervous system diseases and oncology, as disclosed in the risk factors regarding market competition.Source
Strengths
- Proprietary molecular technology platform for targeted delivery to the central nervous systemSource
Company-specific research
Questions worth answering for NTHI
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving NTHI's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can NTHI fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is NTHI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for NTHI to reach sustainable profitability?
- •What future growth or profitability would be needed to justify NTHI's current valuation?
Essential Investment Snapshot
Market Cap
$87.3M
P/E Ratio
-1.1
EPS
$-2.22
52-Week High
$12.10
52-Week Low
$2.52
Beta
0.50
Analyst Target
$15.00
Shares Outstanding
19.2M
Total Debt
$328K
Dividend
No current dividend
Liquidation Value / Share
$-0.96
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for NTHI
Detected from reported data — verify before acting.Severe debt stress
Negative shareholder equity • Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on NTHI.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary molecular technology platform for targeted delivery to the central nervous system.
Potential downside factors
- −Debt risk (severe): Negative shareholder equity.
- −Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$3.03
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 |
|---|---|---|
| Revenue | $0.00 | $40K |
| Cost of Revenue | $58K | $0.00 |
| Gross Profit | -$58K | $40K |
| Research & Development | $5.9M | $3.6M |
| SG&A Expenses | $30.4M | $42.9M |
| Operating Expenses | $41.7M | $58.2M |
| EBITDA | -$43.6M | -$59.6M |
| Operating Income | -$41.8M | -$58.2M |
| Interest Expense | $3.4M | $2.5M |
| Income Before Tax | -$47.2M | -$62.1M |
| Income Tax Expense | $0.00 | $0.00 |
| Net Income | -$47.2M | -$62.1M |
| Basic EPS | $-2.22 | $-3.23 |
| Basic Shares | 24.66M | 19.21M |
| Diluted Shares | 24.66M | 19.21M |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.58
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-17.0%
Cash Change
+1478.2%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS increased 93.3%. Cash increased 1478.2%. Total debt declined 17.0%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries
NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight
NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches
NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward
Rumor Mill · NTHI
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial